Mnemo Therapeutics
Elise Siouve has worked in a variety of roles in the scientific field since 2011. Elise began their career as a Research Intern at the Institute of Molecular and Cellular Biochemistry and Biophysics (IBBMC CNRS) in 2011. Elise then moved on to a Research Trainee role at Janssen, Pharmaceutical Companies of Johnson and Johnson in 2012. In 2013, they worked as a Visiting Research Student - Drug Delivery at the Massachusetts Institute of Technology, Chemical Engineering Department and Koch Institute for Integrative Cancer Research. In 2014, they were an Analyst at Inserm Transfert Initiative. In 2015, they were a Graduate Researcher at Institut Pasteur and a Research Intern at MIT. From 2016 to 2018, they were a PhD Student at the University of Cambridge. Currently, they are a Scientist, Target Discovery (Immuno-Oncology) at Mnemo Therapeutics.
Elise Siouve obtained a Classe Préparatoire aux Grandes Ecoles from Lycée Henri IV. Elise then attended ESPCI Paris - PSL and earned a Double-degree/Advanced master in Science and Technology with a major in Chemistry, as well as Physics and Biology. Following this, they attended Mines Paris and obtained a Double-degree/Master in Science and Executive Engineering, Biotechnology. Currently, they are a PhD candidate at the University of Cambridge.
Mnemo Therapeutics
1 followers
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.